

ArQule partner halts lung cancer drug trial

Mass High Tech: The Journal of New England Technology

Woburn-based biotech company ArQule Inc. has learned that partner Kyowa Hakko Kirin Co., Ltd., which has exclusive development rights to ArQule's lead product candidate tivantinib in Japan, has [suspended patient enrollment](#) [1] in its ongoing Phase 3 trial dubbed ATTENTION.

Source URL (retrieved on 01/26/2015 - 2:15am):

http://www.mdtmag.com/news/2012/08/arqule-partner-halts-lung-cancer-drug-trial?qt-video_of_the_day=0

Links:

[1] http://www.fqs.org/sec-filings/120829/ARQULE-INC_8-K/#ixzz2539Yc8dq